IBI3042 Study in Healthy Participants and Overweight or Obese Participants

NCT07793019 · Recruiting

Last updated 2026-09-22

This clinical trial tests the safety of the study drug IBI3042 in healthy adults and in adults who are overweight or have obesity.

Status Recruiting Currently enrolling participants.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 104 people Planned (estimated).

Who can join Ages 18–55 · all sexes Healthy volunteers accepted.

Timeline Started 2026-09 · est. completion 2028-01

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07793019 ↗

Description as written by the study sponsor.

This is a Phase 1 study of IBI3042, an investigational oral medicine being developed as a potential treatment for overweight and obesity. The study has two parts. Part A will evaluate single doses of IBI3042 in healthy adults. Part B will evaluate repeated doses for 13 weeks in adults with overweight or obesity. The main goal is to assess the safety and tolerability of IBI3042. The study will also evaluate how IBI3042 is processed in the body and explore its effects on body weight and other metabolic measures. Some participants will receive placebo, and some Part B groups will also receive orforglipron for comparison.

Treatments tested

Orforglipron Drug

Oral, corresponding dose regimen according to study cohort (including Part B) .
Matching Placebo Drug

Oral, matching to IBI3042, corresponding dose regimen according to study cohort (including Part A, Part B) .
IBI3042 Drug

Oral, corresponding dose regimen according to study cohort (including Part A, Part B) .

Main thing measured	Number of Participants With Adverse Events (Part A)
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions studied	Overweight, Healthy Participants, Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07793019 ↗